Concepedia

Author

J. Szántó

University of Debrecen

Also Known As

J SZANTO, J Szanto, J Szántó, J. Szanto, J. Szántó, Janos Szanto, Janos Szantó, JÁNOS SZÁNTÓ, János Szántó, Szántó János

156

Publications

1.9K

Citations

21

H-Index

71

Concepts

All Affiliations

University of DebrecenNational Institute of OncologyOttawa HospitalOttawa Regional Cancer FoundationUniversity of Ottawa
JS

About

J. Szántó is an author at University of Debrecen specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

19

787

2

Health Sciences

3

3

78

3

Anesthesia

2

2

74

4

Engineering

1

1

105

5

Applied Physics

1

1

105

J. Szántó

×

32

Publications

1.6K

Citations

21

H-Index

YearCitations

Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

Jean-Marc Nabholtz, Carla I. Falkson, J. Szántó,

Journal of Clinical Oncology

2003

383

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

Carmelo Pozzo, C. Barone, J. Szántó,

Annals of Oncology

2004

157

The Prevalence of Prostate Carcinoma and Its Precursor in Hungary: An Autopsy Study

Györgyike Soós, Ioannis Tsakiris, J. Szántó,

European Urology

2005

125

Lateral electron equilibrium and electron contamination in measurements of head‐scatter factors using miniphantoms and brass caps

X. Allen Li, M. Soubra, J. Szántó,

Medical Physics

1995

105

A prospective comparison of three systems of patient immobilization for prostate radiotherapy

Shawn Malone, J. Szántó, George Perry,

International Journal of Radiation Oncology*Biology*Physics

2000

70

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

Christoph Zielinski, S. Beslija, Zrinka Mršić-Krmpotić,

Journal of Clinical Oncology

2005

63

Increased Production of the Soluble Tumor‐Associated Antigens CA19‐9, CA125, and CA15‐3 in Rheumatoid Arthritis

Éva Szekanecz, Zsuzsa Sándor, Péter Antal‐Szalmás,

Annals of the New York Academy of Sciences

2007

55

Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices

Éva Szekanecz, Gabriella Szűcs, Zoltán Szekanecz,

Journal of Autoimmunity

2008

54

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill,

European Journal of Cancer

2017

46

Influencing effect of heat-treatment on radon emanation and exhalation characteristic of red mud

Zoltán Sas, J. Szántó, János Kovács,

Journal of Environmental Radioactivity

2015

44

Page 1